ClinicalTrials.gg
CompletedNCT00420927OPTIMAUpdated Apr 18, 2012Results posted

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

A Phase 4 interventional study of adalimumab and methotrexate in Rheumatoid Arthritis, sponsored by Abbott. Completed at 170 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-18.

Sponsored by Abbott · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,032
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
5th of 87
1,032 · median 160
Started
2006
with 4 others
Phase 4
33 of 87
1 open now
Registered
16th of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 5 that started in 2006, is one of 33 in phase 4, and was the 16th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

Read the detailed description

This was a 78-week, multicenter, randomized, double-blind, double-treatment period study designed to compare the safety and efficacy of adalimumab and MTX with placebo and MTX in subjects with early RA. Subjects were randomized to receive adalimumab 40 mg every other week (eow) or placebo subcutaneous injections in combination with orally administered MTX for 26 weeks (Period 1). All subjects in all arms received open-label MTX weekly throughout the study (both Period 1 and Period 2).

At Weeks 22 and 26, subjects were assessed for achievement of low disease activity, defined as a DAS28 score below 3.2. DAS28 is a measure of RA disease activity calculated using the number of tender and swollen joints (out of a total of 28), C-reactive protein level (CRP, a blood marker of inflammation), and the patient's global assessment of disease activity (indicated by marking a 10 cm line between very good and very bad). Subjects who achieved low disease activity at Week 22 and 26 in the adalimumab arm at the end of Period 1 were randomized to receive MTX monotherapy (placebo and MTX) or combination therapy (adalimumab and MTX) in a 1:1 ratio for the duration of Period 2 (52 weeks, i.e., to Week 78 of the study). Subjects achieving low disease activity at Week 22 and 26 in the placebo arm (MTX monotherapy) at the end of Period 1 continued to receive MTX monotherapy (and placebo injections in a blinded fashion) for the duration of Period 2. Subjects failing to achieve low disease activity at Week 22 and 26 at the end of Period 1 received open-label combination therapy during Period 2 regardless of treatment assignment in Period 1.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Early Rheumatoid Arthritis
  • Tumor Necrosis Factor Optimization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18 or older and in good health
  • Subject must meet the definition of early rheumatoid arthritis (RA) defined by the 1987-revised American College of Rheumatology (ACR) classification criteria and had disease duration of less than 1 year from diagnosis
  • Subject must have a Disease Activity Score (DAS28, based on C-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed
  • Subject must fulfill at least one of the following three criteria:

    • Rheumatoid factor positive
    • Greater than 1 joint erosion
    • Anti-cyclic citrullinated peptide (CCP) antibody positive.

Exclusion criteria

Exclusion Criteria

  • Subject has previously received systemic anti-tumor necrosis factor (TNF) therapy
  • Subject has received any biologic or therapy within 6 weeks prior to Baseline
  • Subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (DMARDs) or MTX, had been treated with intra-articular or parenteral administration of in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,032 participants (actual)

Study arms

  • Experimental
    ADA+MTX/PBO+MTX (Arm 1)

    Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2

    Biological: adalimumab · Drug: methotrexate · Biological: placebo

  • Experimental
    ADA+MTX/ADA+MTX (Arm2)

    Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2

    Biological: adalimumab · Drug: methotrexate

  • Experimental
    ADA+MTX/OL ADA+MTX (Arm 3)

    Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2

    Biological: adalimumab · Drug: methotrexate

  • Experimental
    PBO+MTX/PBO+MTX (Arm 4)

    Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2

    Drug: methotrexate · Biological: placebo

  • Experimental
    PBO+MTX/OL ADA+MTX (Arm 5)

    Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.

    Biological: adalimumab · Drug: methotrexate · Biological: placebo

Interventions

  • Biologicaladalimumab

    Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

    Also known as: Humira, D2E7

  • Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.

  • Biologicalplacebo

    Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4

    The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

    Time frame: Week 78

Secondary outcomes

  1. Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1

    The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

    Time frame: Week 78

  2. Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78

    The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

    Time frame: Week 78

  3. Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78

    The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

    Time frame: Week 78

  4. Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78

    For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Week 78

  5. Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78

    Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

    Time frame: Week 78

  6. Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78

    Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

    Time frame: Week 78

  7. Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78

    Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

    Time frame: Week 78

  8. Change From Baseline in DAS28 Score at Week 78

    The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

    Time frame: Baseline to Week 78

  9. Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78

    The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

    Time frame: Week 78

  10. Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78

    The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

    Time frame: Week 78

  11. Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78

    The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

    Time frame: Week 78

  12. Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78

    The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

    Time frame: Week 78

  13. Change From Baseline in CDAI Score at Week 78

    The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

    Time frame: Baseline to Week 78

  14. Change From Baseline in SDAI Score at Week 78

    The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

    Time frame: Baseline to Week 78

  15. Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78

    Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.

    Time frame: Baseline to Week 78

  16. Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78

    In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

    Time frame: Week 78

  17. Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78

    In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.

    Time frame: Week 78

  18. Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78

    In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.

    Time frame: Week 78

07

Results

Posted Sep 29, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Started51551700000
Completed46646000000
Not completed495700000
Withdrew: Adverse event191500000
Withdrew: Withdrawal by subject71200000
Withdrew: Lost to follow-up8600000
Withdrew: Lack of efficacy/loss of efficacy1600000
Withdrew: Death2000000
Withdrew: Subject moved/relocated0200000
Withdrew: Noncompliant with study drug1100000
Withdrew: Randomization error1000000
Withdrew: Suspected tuberculosis/positive test1100000
Withdrew: Study site closure0100000
Withdrew: Subject received new diagnosis0200000
Withdrew: Received wrong treatment/incorrect dose0100000
Withdrew: Failed to meet entry criteria8700000
Withdrew: Took prohibited medication1300000
Period 2
Participant flow — Period 2
MilestoneADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Started00102105259112348
Completed00899521697295
Not completed001310431553
Withdrew: Adverse event007317620
Withdrew: Withdrawal by subject001311212
Withdrew: Lost to follow-up0022639
Withdrew: Lack of efficacy/loss of efficacy0021626
Withdrew: Received wrong treatment/incorrect dose0000001
Withdrew: Subject unable to find transportation0000001
Withdrew: Physician decision0000110
Withdrew: Sponsor decision0010001
Withdrew: Randomization error0000110
Withdrew: Noncompliant with study drug0001002
Withdrew: Methotrexate intolerance0000001
Withdrew: Took prohibited medication0000100

Outcome measures

PrimaryNumber of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4

The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 4
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 459739461129
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Chi-squared · p = 0.023P value is from Pearson's chi-square test.
SecondaryNumber of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1

The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07, with scores below 3.2 indicating low disease activity. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 1
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78, Arm 2 vs. Arm 159739461129
Statistical analysis
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.082
SecondaryNumber of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78

The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With DAS28 Low Disease Activity (DAS28 Less Than 3.2) at Week 78718010878185
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.280
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.287
SecondaryNumber of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78

The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With DAS28 Remission (DAS28 Less Than 2.6) at Week 7857777166138
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.026
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.009
SecondaryNumber of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78

For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS Less Than or Equal to 0.5) at Week 78708418277220
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.060
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.063
SecondaryNumber of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78

Subjects were responders if they had greater than or equal to 20% improvement in tender joint count; greater than or equal to 20% improvement in swollen joint count; and greater than or equal to 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 78848917290257
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.395
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.640
SecondaryNumber of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78

Subjects were responders if they had: greater than or equal to 50% improvement in tender joint count; greater than or equal to 50% improvement in swollen joint count; and greater than or equal to 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 78728212078198
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.159
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.217
SecondaryNumber of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78

Subjects were responders if they had: greater than or equal to 70% improvement in tender joint count; greater than or equal to 70% improvement in swollen joint count; and greater than or equal to 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant (C-reactive protein).

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 7857737864137
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.060
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.043
SecondaryChange From Baseline in DAS28 Score at Week 78

The Disease Activity Score (DAS28) is calculated using the number of tender and swollen joints (out of 28 counted), C-reactive protein level, and the patient's global assessment of disease activity. The calculated range of DAS28 is 0.49 to 9.07. A DAS28 less than 2.6 indicates clinical remission, DAS28 2.6 to 3.2 indicates low disease activity, DAS28 3.2 to less than 5.1 indicates moderate disease activity, and DAS28 of 5.1 or greater indicates high disease activity.

Time frame:
Baseline to Week 78
Reported as:
Mean · Scores on a scale
Change From Baseline in DAS28 Score at Week 78
Scores on a scaleADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Change From Baseline in DAS28 Score at Week 78-3.54 ± 1.259-3.71 ± 1.134-2.70 ± 1.531-3.04 ± 1.513-3.07 ± 1.486
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · ANCOVA · p = 0.004Analysis of covariance adjusting for baseline
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · ANCOVA · p = 0.049Analysis of covariance adjusting for baseline
SecondaryNumber of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78

The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Clinical Disease Activity Index (CDAI) Low Disease Activity (CDAI Less Than or Equal to 10) at Week 78758410982195
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.240
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.271
SecondaryNumber of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78

The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Simplified Disease Activity Index (SDAI) Low Disease Activity (SDAI Less Than or Equal to 11) at Week 78737910676192
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.230
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.550
SecondaryNumber of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78

The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Clinical Disease Activity Index (CDAI) Remission (CDAI Less Than or Equal to 2.8) at Week 784758395494
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.301
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.188
SecondaryNumber of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78

The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With Simplified Disease Activity Index (SDAI) Remission (SDAI Less Than or Equal to 3.3) at Week 784555395192
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.314
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.235
SecondaryChange From Baseline in CDAI Score at Week 78

The CDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76.0, with a higher score reflecting worsening disease.

Time frame:
Baseline to Week 78
Reported as:
Mean · Scores on a scale
Change From Baseline in CDAI Score at Week 78
Scores on a scaleADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Change From Baseline in CDAI Score at Week 78-33.30 ± 12.808-33.29 ± 12.964-29.06 ± 16.561-27.63 ± 15.526-31.30 ± 14.769
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · ANCOVA · p = 0.030Analysis of covariance adjusting for baseline
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · ANCOVA · p = 0.403Analysis of covariance adjusting for baseline
SecondaryChange From Baseline in SDAI Score at Week 78

The SDAI is calculated using number of swollen joints (28 joints assessed), number of tender joints (28 joints assessed), patient's global assessment of disease activity, physician's global assessment of disease activity, and acute phase reactant (C-reactive protein). Scores range from 0.1 to 86.0, with a higher score reflecting worsening disease.

Time frame:
Baseline to Week 78
Reported as:
Mean · Scores on a scale
Change From Baseline in SDAI Score at Week 78
Scores on a scaleADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Change From Baseline in SDAI Score at Week 78-35.61 ± 13.527-35.16 ± 13.784-31.00 ± 17.856-29.30 ± 17.120-33.43 ± 15.852
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · ANCOVA · p = 0.036Analysis of covariance adjusting for baseline
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · ANCOVA · p = 0.349Analysis of covariance adjusting for baseline
SecondaryChange From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78

Synovitis was assessed using high-field magnetic resonance imaging (MRI) of the hand and wrist. Images were read and scored according to the Outcomes Measures in Rheumatology Clinical Trials' Rheumatoid Arthritis MRI Scoring System (OMERACT RAMRIS). Synovitis in the wrist and finger joints in the most affected hand was scored from 0 (normal) to 3 (severe), for a maximum total score of 21.

Time frame:
Baseline to Week 78
Reported as:
Mean · Scores on a scale
Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 78
Scores on a scaleADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Change From Baseline in Synovitis Score According to the Rheumatoid Arthritis Magnetic Resonance Imaging (RA MRI) Scoring System (RAMRIS) at Week 782.00 ± 2.121-3.38 ± 2.562-3.25 ± 3.631-3.88 ± 3.351-4.27 ± 4.211
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · ANCOVA · p = 0.037Analysis of covariance adjusting for baseline
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · ANCOVA · p = <0.001Analysis of covariance adjusting for baseline
SecondaryNumber of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78

In the Health Assessment Questionnaire Disability Index (HAQ-DI), participants rated their ability to perform daily tasks on a scale of 0 (without any difficulty) to 3 (unable to do). A mean score of 0-1 represents mild to moderate functional disability, 1-2 represents moderate to severe, 2-3 severe to very severe disability. For the modified Total Sharp score (mTSS), x-rays of hand/wrist and feet joints are scored for erosions (0 to 5) and joint space narrowing (0 to 4). The erosion score and the narrowing score are added to determine the total score, which ranges from 0 (no damage) to 448.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5) and Normal Function (HAQ-DI Less Than 0.5) at Week 784959655384
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.192
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.241
SecondaryNumber of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78

In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (worst joint damage). American College of Rheumatology 70% (ACR70) response indicates at least 70% improvement in tender and swollen joint counts and at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; HAQ-DI; and C-reactive protein.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than or Equal to 0.5), and ACR70 Response at Week 783756404367
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.028
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.014
SecondaryNumber of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78

In the Health Assessment Questionnaire Disability Index (HAQ-DI), a score of 0-1 represents mild to moderate, 1-2 moderate to severe, 2-3 severe to very severe disability. The modified Total Sharp score (mTSS) ranges from 0 (no joint damage) to 448 (severe joint damage). The Disease Activity Score (DAS28) ranges from 0.49 to 9.07, with scores less than 2.6 indicating clinical remission.

Time frame:
Week 78
Reported as:
Number · Participants
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 78
ParticipantsADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)
Number of Subjects With No Radiographic Progression (Change From Baseline in mTSS of Less Than or Equal to 0.5), Normal Function (HAQ-DI Less Than 0.5), and DAS28 Remission (DAS28 Less Than 2.6) at Week 783953384363
Statistical analysis
  • ADA+MTX/ADA+MTX (Arm 2) vs PBO+MTX/PBO+MTX (Arm 4) · Regression, Logistic · p = 0.074
  • ADA+MTX/PBO+MTX (Arm 1) vs ADA+MTX/ADA+MTX (Arm 2) · Regression, Logistic · p = 0.077

Adverse events

Collected over Adverse events reported during Period 1 (Weeks 0 to 26) are presented by Period 1 treatment group. Adverse events reported during Period 2 (Weeks 26 to 78) are presented by Period 2 treatment arm (Arm 1 through Arm 5).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADA+MTX/PBO+MTX (Arm 1)—11/102 (10.8%)28/102 (27.5%)
ADA+MTX/ADA+MTX (Arm 2)—12/105 (11.4%)38/105 (36.2%)
ADA+MTX/OL ADA+MTX (Arm 3)—18/259 (6.9%)106/259 (40.9%)
PBO+MTX/PBO+MTX (Arm 4)—9/112 (8%)44/112 (39.3%)
PBO+MTX/OL ADA+MTX (Arm 5)—32/348 (9.2%)134/348 (38.5%)
Period 1 ADA+MTX—37/515 (7.2%)149/515 (28.9%)
Period 1 PBO+MTX—32/517 (6.2%)128/517 (24.8%)
Most frequent serious events
Showing 10 of 142
Most frequent serious events
EventADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Period 1 ADA+MTXPeriod 1 PBO+MTX
Benign prostatic hyperplasiaReproductive system and breast disorders0/1022/1050/2590/1120/3480/5150/517
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1020/1051/2590/1124/3481/5152/517
Benign mediastinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/1050/2590/1120/3480/5150/517
DizzinessNervous system disorders1/1020/1050/2590/1120/3480/5150/517
GastroenteritisInfections and infestations1/1020/1050/2590/1120/3480/5150/517
Gastrointestinal haemorrhageGastrointestinal disorders1/1020/1050/2590/1120/3480/5151/517
HeadacheNervous system disorders1/1020/1050/2590/1120/3480/5150/517
Herpes zosterInfections and infestations1/1020/1050/2590/1120/3481/5150/517
Kidney ruptureInjury, poisoning and procedural complications1/1020/1050/2590/1120/3480/5150/517
Oesophageal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/1050/2590/1120/3480/5150/517
Most frequent other events
Showing 10 of 12
Most frequent other events
EventADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Period 1 ADA+MTXPeriod 1 PBO+MTX
NauseaGastrointestinal disorders7/1024/10515/2599/11227/34860/51555/517
Upper respiratory tract infectionInfections and infestations5/1025/10529/2597/11227/34835/51538/517
NasopharyngitisInfections and infestations5/1026/10523/2594/11223/34834/51525/517
SinusitisInfections and infestations3/1022/1059/2598/11219/34813/51515/517
CoughRespiratory, thoracic and mediastinal disorders3/1027/10513/2594/11214/34820/51518/517
Urinary tract infectionInfections and infestations2/1025/10512/2595/11222/34825/51522/517
Alanine aminotransferase increasedInvestigations5/1024/10516/2593/11216/34811/51514/517
InfluenzaInfections and infestations3/1026/1059/2593/11211/34822/51512/517
BronchitisInfections and infestations3/1022/10514/2596/11219/34816/51520/517
HypertensionVascular disorders1/1025/1056/2596/1127/34818/51519/517

Baseline characteristics

Age Categorical
Age Categorical(participants)ADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Total
<=18 years00—————0
Between 18 and 65 years418431—————849
>=65 years9786—————183
Age Continuous
Age Continuous(years)ADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Total
Mean50.7 ± 14.4850.4 ± 13.62—————50.6 ± 14.05
Gender
Gender(participants)ADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Total
Female380382—————762
Male135135—————270
Region of Enrollment
Region of Enrollment(participants)ADA+MTXPBO+MTXADA+MTX/PBO+MTX (Arm 1)ADA+MTX/ADA+MTX (Arm 2)ADA+MTX/OL ADA+MTX (Arm 3)PBO+MTX/PBO+MTX (Arm 4)PBO+MTX/OL ADA+MTX (Arm 5)Total
Argentina3229—————61
Australia58—————13
Austria1112—————23
Belgium4140—————81
Canada5758—————115
Czech Republic2219—————41
France48—————12
Germany4341—————84
Hungary810—————18
Mexico2627—————53
Netherlands03—————3
New Zealand33—————6
Norway45—————9
Poland129—————21
Slovakia63—————9
South Africa3132—————63
Spain2530—————55
Sweden1011—————21
United Kingdom2617—————43
United States149152—————301
08

Study locations

170 sites
  • Site Reference ID/Investigator# 4560
    Birmingham, Alabama 35205, United States
  • Site Reference ID/Investigator# 4547
    Birmingham, Alabama 35294-7201, United States
  • Site Reference ID/Investigator# 6222
    Huntsville, Alabama 35801, United States
  • Site Reference ID/Investigator# 4537
    Mobile, Alabama 36608, United States
  • Site Reference ID/Investigator# 6758
    Tuscaloosa, Alabama 35406, United States
  • Site Reference ID/Investigator# 9323
    Hemet, California 92543, United States
  • Site Reference ID/Investigator# 4568
    La Jolla, California 92037-0943, United States
  • Site Reference ID/Investigator# 4535
    Palm Desert, California 92260, United States
  • Site Reference ID/Investigator# 4571
    Santa Monica, California 90404, United States
  • Site Reference ID/Investigator# 9271
    Torrance, California 90505, United States
  • Site Reference ID/Investigator# 10746
    Victorville, California 92395, United States
  • Site Reference ID/Investigator# 4559
    Denver, Colorado 80230, United States
  • Site Reference ID/Investigator# 6229
    Aventura, Florida 33180, United States
  • Site Reference ID/Investigator# 10603
    Lake Mary, Florida 32746, United States
  • Site Reference ID/Investigator# 9325
    Orange Park, Florida 32073, United States
  • Site Reference ID/Investigator# 4550
    Palm Harbor, Florida 34684, United States
  • Site Reference ID/Investigator# 4570
    Sarasota, Florida 34239, United States
  • Site Reference ID/Investigator# 4601
    Tampa, Florida 33614, United States
  • Site Reference ID/Investigator# 4552
    Vero Beach, Florida 32960, United States
  • Site Reference ID/Investigator# 10745
    Meridian, Idaho 83642, United States
  • Site Reference ID/Investigator# 4548
    Chicago, Illinois 60612, United States
  • Site Reference ID/Investigator# 4557
    Springfield, Illinois 62704, United States
  • Site Reference ID/Investigator# 4605
    Wichita, Kansas 67203, United States
  • Site Reference ID/Investigator# 10741
    Wheaton, Maryland 20902, United States
  • Site Reference ID/Investigator# 6417
    Fall River, Massachusetts 02720, United States
  • Site Reference ID/Investigator# 4561
    Dover, New Hampshire 03820, United States
  • Site Reference ID/Investigator# 11222
    Freehold, New Jersey 07728, United States
  • Site Reference ID/Investigator# 6228
    Passaic, New Jersey 07055, United States
  • Site Reference ID/Investigator# 4544
    Albuquerque, New Mexico 87102, United States
  • Site Reference ID/Investigator# 12821
    Bronx, New York 10461, United States
  • Site Reference ID/Investigator# 4534
    Orchard Park, New York 14127, United States
  • Site Reference ID/Investigator# 9324
    Plainview, New York 11803, United States
  • Site Reference ID/Investigator# 4600
    Smithtown, New York 11787, United States
  • Site Reference ID/Investigator# 4549
    Mayfield Village, Ohio 44143, United States
  • Site Reference ID/Investigator# 6227
    Bend, Oregon 97701, United States
  • Site Reference ID/Investigator# 4546
    Duncansville, Pennsylvania 16635, United States
  • Site Reference ID/Investigator# 4564
    West Reading, Pennsylvania 19611-1124, United States
  • Site Reference ID/Investigator# 4558
    Wexford, Pennsylvania 15090, United States
  • Site Reference ID/Investigator# 4533
    Charleston, South Carolina 29406, United States
  • Site Reference ID/Investigator# 7482
    Greenville, South Carolina 29601, United States
  • Site Reference ID/Investigator# 10743
    Jackson, Tennessee 38305, United States
  • Site Reference ID/Investigator# 4562
    Nashville, Tennessee 37205, United States
  • Site Reference ID/Investigator# 4536
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 4538
    Houston, Texas 77074, United States
  • Site Reference ID/Investigator# 6899
    San Antonio, Texas 78217, United States
  • Site Reference ID/Investigator# 6381
    Tyler, Texas 75701, United States
  • Site Reference ID/Investigator# 10744
    Seattle, Washington 98133, United States
  • Site Reference ID/Investigator# 4545
    Glendale, Wisconsin 53217, United States
  • Site Reference ID/Investigator# 4572
    Oak Creek, Wisconsin 53154, United States
  • Site Reference ID/Investigator# 3886
    Buenos Aires, 1426AAL, Argentina
  • Site Reference ID/Investigator# 3888
    Buenos Aires, C1015ABO, Argentina
  • Site Reference ID/Investigator# 6346
    Buenos Aires, C1055AAF, Argentina
  • Site Reference ID/Investigator# 3887
    Quilmes, Argentina
  • Site Reference ID/Investigator# 3889
    San Miguel de Tucuman, T4000AXL, Argentina
  • Site Reference ID/Investigator# 8380
    Campsie, Sydney, 2194, Australia
  • Site Reference ID/Investigator# 6954
    Clayton, 3168, Australia
  • Site Reference ID/Investigator# 6940
    Malvern East, 3145, Australia
  • Site Reference ID/Investigator# 3915
    Graz, 8036, Austria
  • Site Reference ID/Investigator# 3911
    Graz, A-8020, Austria
  • Site Reference ID/Investigator# 3880
    Vienna, 1090, Austria
  • Site Reference ID/Investigator# 3885
    Vienna, 1100, Austria
  • Site Reference ID/Investigator# 3916
    Vienna, 1130, Austria
  • Site Reference ID/Investigator# 7792
    Vienna, 1160, Austria
  • Site Reference ID/Investigator# 3914
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 3909
    Genk, 3600, Belgium
  • Site Reference ID/Investigator# 3881
    Gilly, 6060, Belgium
  • Site Reference ID/Investigator# 3376
    Liege, 4000, Belgium
  • Site Reference ID/Investigator# 6720
    Mechelen, 2800, Belgium
  • Site Reference ID/Investigator# 6718
    Sint-Niklaas, 9100, Belgium
  • Site Reference ID/Investigator# 3910
    Yvoir, 5530, Belgium
  • Site Reference ID/Investigator# 6701
    Burlington, L7R 1E2, Canada
  • Site Reference ID/Investigator# 6834
    Edmonton, T5M 0H4, Canada
  • Site Reference ID/Investigator# 7197
    Halifax, B3H 4K4, Canada
  • Site Reference ID/Investigator# 3883
    Hamilton, L8N 1Y2, Canada
  • Site Reference ID/Investigator# 3884
    Hamilton, L8N 2B6, Canada
  • Site Reference ID/Investigator# 3907
    Montreal, H2L 1S6, Canada
  • Site Reference ID/Investigator# 3903
    Montreal, H3Z 2Z3, Canada
  • Site Reference ID/Investigator# 5178
    Ottawa, K2G 6E2, Canada
  • Site Reference ID/Investigator# 3904
    Richmond, V7C 5L9, Canada
  • Site Reference ID/Investigator# 3912
    Sainte-Foy, Quebec, G1W 4R4, Canada
  • Site Reference ID/Investigator# 3901
    Sarnia, N7T 5W6, Canada
  • Site Reference ID/Investigator# 3906
    St. John's, A1A 5E8, Canada
  • Site Reference ID/Investigator# 6542
    Toronto, M9B 1B1, Canada
  • Site Reference ID/Investigator# 3882
    Victoria, V8V 3P9, Canada
  • Site Reference ID/Investigator# 5616
    Windsor, N8X 5A6, Canada
  • Site Reference ID/Investigator# 5847
    Winnipeg, R3A 1M3, Canada
  • Site Reference ID/Investigator# 3905
    Winnipeg, R3A 1M4, Canada
  • Site Reference ID/Investigator# 3968
    Brno, 65691, Czech Republic
  • Site Reference ID/Investigator# 3971
    Hradec Kralove, 500 05, Czech Republic
  • Site Reference ID/Investigator# 5559
    Ostrava, 72200, Czech Republic
  • Site Reference ID/Investigator# 3969
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 5548
    Uherske Hradiste, 686 01, Czech Republic
  • Site Reference ID/Investigator# 3982
    Amiens, 80054, France
  • Site Reference ID/Investigator# 3979
    Le Mans, 72037, France
  • Site Reference ID/Investigator# 3983
    Paris Cedex 14, 75679, France
  • Site Reference ID/Investigator# 3918
    Strasbourg, 67098, France
  • Site Reference ID/Investigator# 3926
    Bad Nauheim, D-61231, Germany
  • Site Reference ID/Investigator# 3928
    Berlin-Buch, 13125, Germany
  • Site Reference ID/Investigator# 3978
    Damp, 24351, Germany
  • Site Reference ID/Investigator# 3924
    Duesseldorf, 40225, Germany

Showing the first 100 of 170 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9. PubMed 31707982 ↗
  • Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3. PubMed 30076156 ↗
  • Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guerette B, Kupper H, Smolen JS. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2018 Feb;77(2):289-292. doi: 10.1136/annrheumdis-2017-211871. Epub 2017 Nov 16. PubMed 29146743 ↗
  • Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017. PubMed 29018564 ↗
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guerette B, Kupper H, Redden L, Arora V, Kavanaugh A. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Erratum In: Lancet. 2014 Jan 25;383(9914):308. PubMed 24168956 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2007
First posted
Jan 11, 2007
Start
Dec 2006
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Sep 29, 2011
Last update
Apr 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00420927
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Jan 11, 2007
Start date
Dec 2006
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Sep 29, 2011
Last update
Apr 18, 2012

Study contacts

Laura Redden, MD, PhD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion